Table 1

HLA-A2 and/or DR4-positive RCC patients evaluated in this study

Individual SLR designations reflect specimen number based on date harvested. In 5 cases, both pre- and (6 weeks) post-therapy blood specimens were available for analysis, as indicated. Where indicated, the time of peripheral blood isolation (in months) post-therapy is provided. HLA-A2 and -DR4 status was determined using allele-specific monoclonal antibodies and flow cytometry gating on peripheral blood monocytes, as described in “Materials and Methods.” Immunohistochemical stained tumor biopsies were available from 14 patients and were stained for EphA2 expression as outlined in “Materials and Methods.” EphA2 expression is indicated on an arbitrary 0 to 4+ scale.

RCC patientAgeSexStageTreatmentDisease status at time of evaluation (months)HLA typingTumor expression EphA2
A2 (+/−)/DR4 (+/−)
SLR30-pre63FINoneLocal Dis.+NAa
SLR3166MISLocal Dis.+2+
SLR3262FISLocal Dis.+2+
SLR3354FISLocal Dis.+3+
SLR3471MINoneLocal Dis.++NA
SLR3575FINoneLocal Dis.++NA
SLR36-pre60MINoneLocal Dis.++NA
SLR3752MINoneLocal Dis.+NA
SLR38-pre69MINoneLocal Dis.+NA
SLR3965MISNED (3)+3+
SLR30-post63FISNED (1.5)+NA
SLR4053MISNED (3)+NA
SLR36-post60MISNED (2)++NA
SLR4164FISNED (2)+2+
SLR38-post69MISNED (2)+3+
SLR4258FISLocal Dis. (3)+3+
SLR4353FISLocal Dis. (1.5)+3+
SLR44-pre69MIVNoneMets.+NA
SLR4565MIVSMets+4+
SLR4645FIVSMets+0
SLR4753FIVSNED (1.5)+NA
SLR4854MIVSMets. (61)+NA
SLR4952FIVS, R, IFN-α, IL-2Mets. (41)+2+
SLR44-post69MIVSMets (2)+4+
SLR5054MIVS, R, CMets (21)+NA
SLR5141MIVS, R, IL-2Mets++NA
SLR5258MIVS, R, IFN-αMets++NA
SLR5352MIVSMets+NA
SLR5449FIVC, IL-2Mets++NA
SLR5579MIVC, IFN-αMets++NA
SLR5656MIVR, C, IFN-α, IL-2Mets+NA
SLR5768FIVSMets+3+
SLR5855FIVNoneMets++NA
SLR5952FINoneLocal Dis.+NA
SLR60-pre58MINoneLocal Dis.+NA
SLR6160MISLocal Dis.+2+
SLR6264MISNED (3)+NA
SLR6353FISNED (1.5)+NA
SLR60-post58MISNED (2)+NA
SLR6465MISNED (10)+NA
SLR6553MIISLocal Dis.+NA
SLR6645MIVNoneMets.+NA
SLR6757MIVC, RMets+NA
SLR6869MIVS, R, CMets+NA
SLR6949MIVS, C, R, IFNα, IL-2Mets+NA
  • a C, chemotherapy; IFN-α, recombinant IFN-α therapy; IL-2, recombinant interleukin-2 therapy; Mets, metastatic disease; NA, not available for evaluation; NED, no evidence of disease; R, radiotherapy; S, surgery.